利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

1023 条记录 (耗时 0.027 秒)

    TOPICAL VITAMIN D ORAL SUPPLEMENT COMPOSITIONS
    36.
    发明公开
    TOPICAL VITAMIN D ORAL SUPPLEMENT COMPOSITIONS 审中-公开
    维生素D局部口腔食品补充组合物

    公开(公告)号：EP2887945A1

    公开(公告)日：2015-07-01

    申请号：EP13844920.2

    申请日：2013-10-10

    申请人： Premier Dental Products Company

    发明人： MCHALE, William A. ,  BROWN, Dale G.

    IPC分类号： A61K31/59

    CPC分类号： A61K31/592 ,  A61K9/006 ,  A61K9/06 ,  A61K31/593 ,  A61K47/10

    摘要： Topical, vitamin D, oral supplement compositions useful in treating oral inflammation comprising vitamin D in an aqueous-free emulsion containing a trans-oral mucosal absorption facilitator, where said emulsion forms a mucoadhesive coating in the presence of saliva; wherein saliva dissolution of the mucoadhesive gel releases vitamin D and the trans-oral mucosal, absorption facilitator; effecting: vitamin D passive diffusion; regulating in vivo availability and immune response of vitamin D; and maintaining adequate levels of circulating vitamin D while minimizing the risk of hypercalcemia.

    METHOD OF TREATING AND PREVENTING SECONDARY HYPERPARATHYROIDISM
    39.
    发明授权
    METHOD OF TREATING AND PREVENTING SECONDARY HYPERPARATHYROIDISM 有权
    方法用于治疗和预防继发甲状旁腺功能亢进

    公开(公告)号：EP2037936B1

    公开(公告)日：2014-06-11

    申请号：EP07840277.3

    申请日：2007-06-21

    申请人： Proventiv Therapeutics, LLC ,  Cytochroma Inc.

    发明人： BISHOP, Charles, W. ,  CRAWFORD, Keith, H. ,  MESSNER, Eric, J. ,  PETKOVICH, P. Martin ,  HELVIG, Christian, F.

    IPC分类号： A61K31/59 ,  A61P5/20

    CPC分类号： A61K31/593 ,  A61K9/48 ,  A61K31/59 ,  A61K31/592

    摘要： A method of treating elevated blood levels of iPTH by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in a patient by administering, as necessary, both Vitamin D repletion and Vitamin D hormone replacement therapies, is disclosed. The blood concentrations of 25-hydroxyvitamin D are increased to and maintained at or above 30 ng/mL, and blood concentrations of 1,25-dihydroxyvitamin D are increased to or maintained within a patient's normal historical physiological range for 1,25-dihydroxyvitamin D without causing substantially increased risk of hypercalcemia, hyperphosphatemia or over suppression of plasma iPTH in the patient. The blood levels of 25-hydroxyvitamin D are maintained at or above 30 ng/mL between doses of Vitamin D repletion therapies, and the blood levels of 1,25-dihydroxyvitamin D are maintained in the patient's normal historical physiological range between doses of Vitamin D hormone replacement therapies. In one aspect, the disclosure includes methods wherein the blood concentration of 25-hydroxyvitamin D during treatment comprises predominantly 25-hydroxyvitamin D 3 , and/or wherein the method includes administering predominantly or solely 25-hydroxyvitamin D 3 for 25-hydroxyvitamin D repletion and/or maintenance.